IGC Pharma (IGS1) Stock Overview
A clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
IGS1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IGC Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.26 |
| 52 Week High | US$0.53 |
| 52 Week Low | US$0.23 |
| Beta | 0.33 |
| 1 Month Change | 1.59% |
| 3 Month Change | -26.86% |
| 1 Year Change | -18.47% |
| 3 Year Change | -23.99% |
| 5 Year Change | -79.43% |
| Change since IPO | -97.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| IGS1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 9.4% | 4.7% | 2.6% |
| 1Y | -18.5% | 15.2% | 16.5% |
Return vs Industry: IGS1 underperformed the German Pharmaceuticals industry which returned 16.3% over the past year.
Return vs Market: IGS1 underperformed the German Market which returned 15.5% over the past year.
Price Volatility
| IGS1 volatility | |
|---|---|
| IGS1 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IGS1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IGS1's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 70 | Ram Mukunda | igcpharma.com |
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders.
IGC Pharma, Inc. Fundamentals Summary
| IGS1 fundamental statistics | |
|---|---|
| Market cap | €24.34m |
| Earnings (TTM) | -€5.54m |
| Revenue (TTM) | €950.50k |
Is IGS1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGS1 income statement (TTM) | |
|---|---|
| Revenue | US$1.11m |
| Cost of Revenue | US$595.00k |
| Gross Profit | US$511.00k |
| Other Expenses | US$6.96m |
| Earnings | -US$6.45m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | 46.20% |
| Net Profit Margin | -582.82% |
| Debt/Equity Ratio | 1.6% |
How did IGS1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/09 11:50 |
| End of Day Share Price | 2026/01/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IGC Pharma, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |